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WEB EXTRA MATERIAL 
 
Supplementary methods: 
 
Disease overview 
Inclusion body myositis (IBM) is an acquired inflammatory myopathy with onset usually over 50 years of age with a male 
predominance and the quadriceps being the predominant muscle affected in the lower limbs. There are currently no treatments 
with proven efficacy despite numerous trials.1 Charcot-Marie-Tooth disease (CMT) is an umbrella term for the hereditary motor 
and sensory neuropathies with a combined prevalence of around 1:2500 and over 70 causative genes identified. The most common 
type is CMT1A representing 50% of all CMT with progressive distal weakness from childhood.2 Recent trials have been 
hampered by insensitive outcome measures.3 
 
Exclusion criteria: (all subjects) 
• Concomitant neuropathy/myopathy 
• Very advanced disease state that precludes travelling 
• Severe cardiovascular, renal, or other end-stage-organ-disease states or any other major comorbidities (e.g. any active 
malignancy, definite cognitive impairment, psychiatric disease, heart or lung failure, orthopedic or rheumatologic disorders) 
• Pregnancy and active nursing (breast feeding) 
• Inadequate contraception in women of child bearing age. 
• Contra-indication to MRI (metallic fragments, clips or devices in the brain, eye, spinal canal, etc; magnetically activated 
implanted devices, such as cardiac pacemakers, insulin pumps, neurostimulators and cochlear implants; claustrophobia) 
• Existing radiculopathy or lower back pain 
• Surgery to feet within 12 months of beginning of study or during the study 
 
Clinical Strength Grading (MRC Scale) 
The following movements were assessed: 
• Neck: flexion and extension 
• Upper limbs: shoulder abduction, elbow extension, elbow flexion, wrist extension, wrist flexion, finger extension, 
forefinger abduction, little finger abduction, thumb abduction, long finger flexors, short finger flexors 
• Lower limbs: hip flexion, hip extension, hip abduction, hip adduction, knee flexion, knee extension, ankle dorsiflexion, 
ankle plantarflexion, ankle eversion, ankle inversion, big toe extension 
Muscle strength was assessed using a modified MRC scale5 with 5: normal strength, 5-: barely detectable weakness, 4+: gravity 
and moderate to maximal resistance, 4: Gravity and moderate resistance, 4-: Gravity and minimal resistance, 3: Full range of 
motion against gravity only, 2: Movement when gravity is eliminated, 1: Flicker of movement seen or felt, 0: No movement. 
Upper limb/neck and lower muscle scores were summed to obtain a total upper limb/neck and total lower limb score for each 
subject. For this purpose 5- was scored as 4.75, 4+ as 4.25 and 4- as 3.75. The maximum score obtainable was 120 upper 
limb/neck and 110 for lower limb. 
 
Myometry protocol 
All but two initial assessments and all follow up assessments were performed by a single neurologist. Myometry was performed 
according to the table below. Knee extension, knee flexion, ankle dorsiflexion, and ankle plantarflexion were assessed bilaterally 
using both isometric and isokinetic protocols and the maximum torque in Nm recorded for analysis. Isometric assessments 
consisted of four attempts of 3 seconds duration with 10s interval of which the best attempt was selected. For the isokinetic 
assessments, following a practice run and 10s interval, three successive movements through full range were performed and the 
highest value obtained selected. The machine setup was recording at first visit using the included software, which was then 
retrieved to allow identical set-up on repeat testing. A single observer performed over 90% of assessments. All measurements are 
stored within the HUMAC NORM system, and were checked for artefacts before being exported into IBM-SPSS for analsysis. An 
additional overall strength for each movement was calculated by taking the mean of all assessment methods. The Myometry 
assessment either occurred following the MRI or with at least a 60 minute gap if preceding to minimise any potential MRI effects 
secondary to physical activity. 
 
Joint Type Movement Angle 
Knee 
(right then left) 
Isometric 
Extension° 45° 
Extension 90° 
Flexion 45° 
Flexion 90° 
Isokinetic 
Extension/Flexion 60°/s 
Extension/Flexion 120°/s 
Ankle (left then right) 
Isometric 
Plantarflexion 10° 
Dorsiflexion 10° 
Isokinetic Plantarflexion/Dorsiflexion 60°/s 
 
 
MRI Protocol 
 
Selection of musculature 
Lower limb muscles were chosen as the region for study as they are a key site of pathology in both CMT1A (lower calf)2 and IBM 
(quadriceps)1 and weakness is these areas is a key cause of disability in these patient groups.  Furthermore lower limb imaging is 
practical compared with dedicated upper limb image: both limbs may be imaged simultaneously lowering scanning times and 
lower limb imaging is in our experience more comfortable for participants. 
 
Block positioning 
Imaging was performed using a multi-channel peripheral angiography coil (Siemens ‘PA Matrix’) and ‘spine matrix’ coil 
elements supplemented with a body surface coil for proximal thighs. Before scanning the distance between the anterior superior 
iliac spine and the superior border of the patella was measured and thigh-level imaging volumes were centred one third of this 
distance above the patella superior border. Similarly calf-level imaging volumes were centred below the tibial tuberosity by one 
quarter of the total distance from the tibial tuberosity to the lateral malleolus. The derived distances were recorded and used for 
follow up imaging. 
 
Field of View (FOV) 
Both limbs were scanned within the FOV. Axial FOVs were 41x20.5cm (thigh) and 40x18.8cm (calf) 
 
3-Point Dixon Fat-Fraction (FF) Quantification 
For Dixon FF measurements,6 three 2D gradient-echo acquisitions were performed with echo-times 
(TE1/TE2/TE3=3.45/4.60/5.75ms, TR=100ms, flip angle=10o, bandwidth 420Hz/pixel, NEX=4, 10 x 10mm slices with 10mm 
gap, 512x256matrix (thigh), 512x240matrix calf, iPat=2). Phase unwrapping was performed using PRELUDE (FSL, FMRIB, 
Oxford)7 and after fat (F) and water (W) image decomposition, FF calculated as FF = 100% x F/(F+W).  
 
The TE=3.45ms image was used for the region of interest (ROI) placement and as a reference for inter-method image 
interpolation and registration (calf) using FLIRT (FSL, FMRIB, Oxford), such that that the same ROIs could be applied to extract 
data from all maps.  
 
T2-Relaxometry 
Dual-contrast turbo-spin-echo (TSE) images (6500/13/52ms or 6500/16/56ms; 10x10mm slices with 10mm gap, iPat=2, 
BW=444Hx/pixel, refocusing flip angle 180º, NEX=1, 6/8 k-space sampling, 256x128matirx (thigh), 256x120matrix (calf)) were 
acquired. Pseudo-T2 was calculated from the respective pixel intensities ITE1 and ITE2 from the TE1 and TE2 images as T2=
)/ln( 21
12
TETE II
TETE − . The different echo times were the result of altered constraints following a routine scanner software upgrade which 
occurred after 54 baseline and 6 follow-up scans had been completed. Analysing control values pre- and post-upgrade suggested a 
systematic bias between pre- and post-upgrade T2 values. By comparing the observed relationship between FF and T2 
measurements pre- and post-software upgrade a correction equation was determined separately for thigh muscles (corrected T2 = 
1.0606 x post-upgrade T2 + 1.1522) and calf muscles (corrected T2 = 1.0933 x post-upgrade T2 – 0.0245). These corrections were 
applied to all post-upgrade T2 measurements to ensure pre- and post-upgrade T2 measurements were comparable. Parameters for 
the other quantitative sequences were not affected by this upgrade, and analysis of the control values pre- and post-upgrade 
indicated no systematic bias in these values was introduced by the software upgrade. 
 
B1 Mapping 
Separate TSE images (TR/TE=7000/11ms, 128x64 matrix, 40 contiguous 10mm slices, BW=429Hx/pixel, 1/2 k-space sampling) 
yielded image intensities V1 and V2 acquired with nominal excitation α1 and α2 of 60o and 120o. B1 deviation was mapped 
according to 1121 /)2/arccos( αVVB Dev = .8 
 
Magnetization Transfer Ratio (MTR) Imaging 
MTRs were calculated from two 3D-FLASH images with (M1) and without (M0) an MT pre-pulse (500° amplitude, 1200Hz 
offset, 10ms duration) (TR/TE=65/3ms or 68/3ms, α=10º, BW=440Hz/pixel, NEX=1, 6/8 k-space sampling, iPat=2, 40x5mm 
longitudinal phase encoding partitions, 256x128matrix (thigh), 256x120matrix (calf)) according to MTR = (M0-M1)/M0 x 100 
percentage units (p.u.). Percentage units were used by convention to avoid ambiguity with fractional change expressed as a 
percentage.9 MTR maps were RF-inhomogeneity corrected using the B1 maps according using a mean-over-all-subjects B1 
inhomogeneity correction factor of k = 0.0085.10  
 
Analysis Slice Selection  
For the baseline scan the fifth most superior slice was used in the thigh and the sixth slice in the calf unless all muscles were not 
visible in which case an adjacent slice was selected. The ROI were drawn on the follow up acquisition on the slice closest to that 
used for the first scan, determined on the basis of measured distance from bony landmarks (tibial plateau or tip of the fibular head) 
identified on the 3D-FLASH images. 
After extraction, all data were cross-checked for outliers and any errors rectified.  
 
Data analysis 
Whole muscle ROIs were defined to encompass the entire muscle cross sectional area (CSA) to the fascia whilst “small” ROIs 
were defined in a consistent anatomical location within each muscle to avoid contamination with fascia or vessels and to allow for 
minor anatomical movement between acquisitions (figure 2A). Left and right limb ROIs were defined for all muscles at these 
levels: rectus femoris, vastus lateralis, vastus intermedius, vastus medialis, semimembranosus, semitendinosus, biceps femoris, 
adductor magnus, sartorius, gracilis, tibialis anterior, peroneus longus, lateral gastrocnemius, medial gastrocnemius, soleus and 
tibialis posterior muscles. 
 
Minor adjustments to small ROI were made where imperfect registration meant ROI were no longer wholly within the target 
muscle. Whole muscle ROIs were transferred to the inherently co-registered FF maps only. The whole muscle ROIs from the 
unprocessed Dixon acquisition were not used for T2 and MTR analysis to avoid ROI contamination with non-muscle tissue, a 
particular problem for these measures, at the region boundaries due to minor subject movement between acquisitions. ROIs 
including areas of gross artefact were excluded from the analysis.  Of 248 total maps, 5 fat fraction maps (2%), 2 T2 maps (1%) 
and 14 MTR maps (5%) were excluded due to technical issues or widespread artefact.  Artefact in the anterior right thigh of the 
MTR maps limited analysis in this region as reported in the application of this protocol to healthy volunteers.4 This is 
demonstrated in the number of each ROI analysed in figure e1. 
 
Statistical methods 
If the follow-up duration differed from 12 months the magnitude of change was converted to an annualised value. Outcome 
measure 12 month SRMs were calculated for each measure as the mean change between baseline and follow-up divided by the 
standard deviation of that change, and categorised by magnitude according to Cohen’s suggestion: <0·2 minimal responsiveness; 
0·2-0·5 small responsiveness; 0·5-0·8 moderate responsiveness; >0·8 large responsiveness. 
Table e1: Baseline myometry statistics by group  
 
Movement Type Side/angle CMT Control (CMT) IBM Control (IBM 
Knee 
Extension 
Isometric 
Right at 45° 111.1 ± 48.9 (24-209) 155.6 ± 47.3 (73-259) 35.4 ± 38.4 (0-146) 138.6 ± 60 (18-259) 
Left at 45° 109.7 ± 47.6 (38-217) 152.2 ± 45.5 (73-231) 33.5 ± 38.3 (0-145) 138.9 ± 48.7 (62-218) 
Right at 90° 112.2 ± 58.4 (45-290) 159.3 ± 62.6 (84-292) 29.2 ± 23.9 (2-91) 136.6 ± 55.4 (18-252) 
Left at 90° 106.6 ± 60.8 (43-277) 142 ± 50.5 (72-247) 28.3 ± 26.5 (0-94) 128.5 ± 43.3 (72-216) 
Isokinetic 
Right at 60°/s 87 ± 45 (12-184) 133.5 ± 49.1 (49-239) 25 ± 22 (0-87) 116.8 ± 45.4 (18-190) 
Left at 60°/s 87.4 ± 42.1 (23-165) 127.6 ± 40 (52-202) 24.2 ± 24.4 (0-94) 115.7 ± 38 (52-174) 
Right at 120°/s 70 ± 32.5 (27-138) 106.9 ± 40.8 (41-206) 20.2 ± 18.3 (0-71) 93 ± 38.5 (13-170) 
Left at 120°/s 68.6 ± 35.3 (26-138) 102.5 ± 35.2 (45-165) 19 ± 19.7 (0-80) 91.4 ± 32.8 (45-145) 
Knee 
Flexion 
Isometric 
Right at 45° 65.8 ± 26.9 (33-115) 86.6 ± 28.9 (53-141) 49.6 ± 27.4 (2-110) 80 ± 29.1 (33-140) 
Left at 45° 66.3 ± 27.5 (33-113) 81.8 ± 22.9 (35-132) 48.8 ± 25.5 (2-106) 74.9 ± 27.7 (35-132) 
Right at 90° 47.9 ± 20.4 (14-92) 64.7 ± 27.1 (31-127) 28.9 ± 18.1 (0-68) 54.7 ± 18.9 (26-106) 
Left at 90° 45.4 ± 20.9 (15-83) 57.8 ± 24.3 (28-110) 31.3 ± 20.9 (0-77) 49.3 ± 18.3 (24-95) 
Isokinetic 
Right at 60°/s 46.6 ± 18.8 (9-81) 70 ± 21.7 (28-123) 34.9 ± 21.4 (0-81) 64.5 ± 21 (27-99) 
Left at 60°/s 45.1 ± 20 (8-85) 62.9 ± 17.3 (20-85) 37 ± 21.5 (0-80) 62.4 ± 22.7 (20-104) 
Right at 120°/s 35.1 ± 16.8 (14-72) 55.5 ± 19.7 (22-102) 26.1 ± 17.7 (0-72) 50.8 ± 17.8 (22-87) 
Left at 120°/s 34.5 ± 18.6 (12-75) 50 ± 14.9 (20-77) 25.9 ± 17 (0-57) 48.5 ± 18.2 (20-84) 
Ankle 
Plantar-
flexion 
Isometric 
Right at 10° 33.7 ± 19.6 (1-64) 66.6 ± 20.8 (35-106) 34.4 ± 18.7 (3-64) 56.2 ± 19.1 (28-92) 
Left at 10° 32.7 ± 19.8 (0-64) 65.1 ± 19.5 (33-108) 33.6 ± 16.7 (4-60) 57.2 ± 23.7 (33-110) 
Isokinetic 
Right at 60°/s 18.7 ± 12.8 (5-58) 57.7 ± 21.6 (24-107) 24.1 ± 14.3 (0-54) 46.1 ± 17 (22-75) 
Left at 60°/s 19 ± 12.4 (4-53) 58.6 ± 21.7 (22-115) 29.2 ± 17.2 (7-71) 46.9 ± 20.5 (8-79) 
Ankle 
Dorsi-
flexion 
Isometric 
Right at 10° 9.7 ± 8.1 (0-31) 35.7 ± 13.7 (16-60) 15 ± 12.9 (0-38) 33 ± 14.9 (7-60) 
Left at 10° 10 ± 7.8 (0-27) 34.5 ± 13.1 (12-58) 15.4 ± 12.5 (0-38) 32.6 ± 14.2 (8-58) 
Isokinetic 
Right at 60°/s 11.9 ± 8.4 (0-30) 25.4 ± 8.5 (12-42) 11.8 ± 12.5 (0-50) 23.3 ± 9.2 (9-42) 
Left at 60°/s 11.9 ± 11 (0-43) 24.5 ± 8.7 (7-37) 11.8 ± 8.3 (0-26) 23.2 ± 9 (7-35) 
Ankle 
Inversion 
Isometric 
Right at 0° 15.6 ± 10 (0-37) 20.4 ± 7.1 (9-33) 11.9 ± 7.3 (0-27) 18.1 ± 6.4 (9-33) 
Left at 0° 14.8 ± 10.4 (0-45) 20.1 ± 7.1 (7-30) 11.5 ± 6.7 (0.15-26) 17.7 ± 6.7 (7-30) 
Isokinetic 
Right at 60°/s 16 ± 9.9 (0-38) 25.4 ± 7.9 (11-39) 14.9 ± 9.6 (3-34) 22.7 ± 7.8 (9-34) 
Left at 60°/s 14.3 ± 9.5 (3-35) 25.6 ± 8.9 (11-43) 17.1 ± 10.2 (3-35) 21.8 ± 8.6 (11-39) 
Ankle 
Eversion 
Isometric 
Right at 0° 7.1 ± 4.1 (1-14) 22 ± 7.6 (9-37) 9.6 ± 5.9 (0-22) 19 ± 7.6 (9-34) 
Left at 0° 7.7 ± 4.8 (0-18) 21.4 ± 7.1 (11-34) 10.2 ± 6.5 (0-20) 17.5 ± 6.9 (8-31) 
Isokinetic 
Right at 60°/s 8.4 ± 4 (1-15) 17.3 ± 5.6 (9-28) 9.2 ± 5 (0-20) 15.1 ± 5.6 (8-23) 
Left at 60°/s 7.8 ± 3.1 (3-14) 17.4 ± 5.8 (9-30) 9.3 ± 5.8 (0-24) 16.2 ± 7.1 (8-33) 
 
Data are mean ± standard deviation (range). Isometric values are the peak torque at the fixed angle listed whilst isokinetic values 
are the peak torque at the fixed speed noted. Both CMT1A patients and IBM patients have significantly (p<0.01 for all) reduced 
strength than their matched control groups for all measurements. 
 
T
able e2: baseline individual m
uscle M
R
I values in C
M
T
 and m
atched controls 
 M
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C
M
T 
C
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M
T) 
FF (%
) 
T2 (m
s) 
M
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FFw
 (%
) 
FF (%
) 
T2 (m
s) 
M
TR
 (p.u.) 
FFw
 (%
) 
R
ight R
ectus Fem
oris 
3.6 ± 12.1 (20) 
46.8 ± 13.7 (16) 
28.9 ± 9.3 (5) 
6.3 ± 13 (20) 
0.7 ± 1 (20) 
40.8 ± 5.5 (17) 
33.3 ± 1.9 (3) 
2.7 ± 1.9 (19) 
R
ight V
astus M
edialis 
2 ± 2.9 (20) 
43.8 ± 7.8 (20) 
31.6 ± 2.2 (10) 
4.4 ± 8.1 (20) 
1 ± 0.8 (20) 
40.9 ± 3.9 (19) 
32.6 ± 1.9 (8) 
2.2 ± 1.1 (19) 
R
ight V
astus Interm
edius 
3 ± 5.8 (20) 
44.6 ± 11.5 (20) 
30.3 ± 4.8 (14) 
4.3 ± 10.4 (20) 
1 ± 1.1 (20) 
38.4 ± 2.8 (20) 
33.2 ± 1.8 (14) 
2 ± 1.6 (19) 
R
ight V
astus Lateralis 
5.4 ± 19.1 (20) 
49.6 ± 26.2 (19) 
31 ± 6.6 (20) 
6.2 ± 14 (20) 
1.2 ± 0.9 (20) 
42.2 ± 4.8 (18) 
32.5 ± 1.3 (19) 
2.6 ± 1.3 (19) 
R
ight Sem
im
em
branosus 
3.5 ± 4.5 (20) 
48.5 ± 8.8 (19) 
30.5 ± 2.9 (20) 
6.7 ± 5.5 (20) 
2.5 ± 3.1 (20) 
44.9 ± 6.4 (20) 
31.4 ± 1.6 (18) 
4.6 ± 2.9 (19) 
R
ight Sem
itendinosus 
2.3 ± 2.7 (20) 
47.4 ± 8.3 (20) 
31.2 ± 2.8 (20) 
6.3 ± 5.3 (20) 
1.1 ± 0.7 (20) 
43.3 ± 4 (20) 
32.1 ± 1.1 (18) 
3.6 ± 2.7 (19) 
R
ight B
iceps Fem
oris 
2.7 ± 3.5 (20) 
47.8 ± 7.4 (19) 
30.5 ± 2.6 (20) 
4.6 ± 4.7 (20) 
2 ± 1.4 (20) 
46.5 ± 5 (18) 
31.2 ± 1.3 (18) 
3.7 ± 2.4 (19) 
R
ight A
dductor M
agnus 
2.3 ± 4 (20) 
45 ± 7.3 (20) 
31.9 ± 2.2 (20) 
5.1 ± 7.3 (20) 
2 ± 3 (20) 
43 ± 5.6 (20) 
32.1 ± 1.6 (18) 
3.8 ± 3.4 (19) 
R
ight Sartorius 
5.9 ± 10.6 (20) 
48.3 ± 11.1 (20) 
27.7 ± 5.4 (13) 
9.5 ± 8.6 (20) 
3.6 ± 3.8 (20) 
43.6 ± 6.1 (19) 
31.9 ± 1.8 (8) 
5.9 ± 2.8 (19) 
R
ight G
racilis 
3.1 ± 4.6 (19) 
44 ± 7.5 (20) 
31.8 ± 3.2 (19) 
6.8 ± 5.7 (20) 
1.8 ± 1.7 (20) 
39.5 ± 3.5 (20) 
32.8 ± 1.4 (17) 
4.1 ± 2.3 (18) 
Left R
ectus Fem
oris 
2.7 ± 8.2 (20) 
45.4 ± 17.1 (20) 
31.6 ± 4.6 (16) 
6 ± 11.4 (20) 
1.1 ± 1.6 (20) 
38.4 ± 4.8 (18) 
32.8 ± 1.9 (18) 
3 ± 2.3 (19) 
Left V
astus M
edialis 
2.7 ± 5.4 (20) 
44.3 ± 9.2 (20) 
31.5 ± 3.4 (19) 
5.3 ± 9.3 (20) 
1.2 ± 1.3 (20) 
42 ± 4.7 (20) 
32.3 ± 1.2 (18) 
2.7 ± 1.4 (19) 
Left V
astus Interm
edius 
8.2 ± 21.7 (20) 
51.8 ± 29.6 (20) 
29 ± 7.7 (19) 
6.1 ± 12.6 (20) 
1.3 ± 1 (20) 
42.3 ± 5.5 (19) 
31.7 ± 1.4 (19) 
2 ± 1.3 (19) 
Left V
astus Lateralis 
4.8 ± 15.1 (20) 
44.5 ± 18.7 (20) 
30.8 ± 5.6 (19) 
7.2 ± 15.1 (20) 
1.6 ± 1.2 (20) 
40.6 ± 3 (19) 
32.1 ± 1.2 (19) 
3.4 ± 1.7 (19) 
Left Sem
im
em
branosus 
3 ± 1.8 (20) 
43.5 ± 4.4 (20) 
29.6 ± 2.4 (16) 
6.9 ± 5.5 (20) 
2.3 ± 1.8 (19) 
42 ± 5.1 (20) 
30.9 ± 1.1 (17) 
4.2 ± 2.6 (17) 
Left Sem
itendinosus 
2.6 ± 3.1 (20) 
42.7 ± 5.6 (20) 
31.1 ± 2.6 (18) 
6.4 ± 5.4 (20) 
1.4 ± 1.2 (19) 
40.8 ± 4.3 (20) 
31.9 ± 1 (18) 
4.1 ± 2.3 (17) 
Left B
iceps Fem
oris 
3 ± 4.2 (20) 
44.8 ± 7.4 (20) 
30.7 ± 3.2 (19) 
6.1 ± 5.7 (19) 
2.6 ± 2.2 (20) 
43.5 ± 6.4 (20) 
31.8 ± 1.4 (19) 
4.8 ± 2.8 (19) 
Left A
dductor M
agnus 
2 ± 2.2 (20) 
41.9 ± 4.2 (20) 
30.7 ± 2.1 (18) 
6.2 ± 8.9 (19) 
2 ± 2.3 (20) 
42.4 ± 5.2 (20) 
31.6 ± 1.3 (18) 
3.9 ± 3.3 (19) 
Left Sartorius 
5.5 ± 9.9 (20) 
47.4 ± 13.2 (20) 
30.2 ± 4.6 (17) 
9.1 ± 9.1 (20) 
2.7 ± 2.9 (20) 
42 ± 6 (20) 
31.8 ± 2.3 (16) 
6.7 ± 3.5 (19) 
Left G
racilis 
5 ± 11.5 (20) 
43.7 ± 13.4 (20) 
30.4 ± 4.2 (18) 
7.5 ± 9.7 (20) 
1.8 ± 1.6 (20) 
38.1 ± 3.8 (20) 
32.4 ± 1.4 (18) 
5 ± 2 (19) 
R
ight Tibialis A
nterior 
12.6 ± 23.6 (20) 
57.2 ± 29.7 (20) 
23.4 ± 8.4 (16) 
14 ± 21.2 (20) 
0.7 ± 0.7 (19) 
36.9 ± 2.3 (20) 
30.5 ± 1.4 (17) 
1.5 ± 0.9 (19) 
R
ight Peroneus Longus 
21.9 ± 30.5 (20) 
66.4 ± 36.1 (20) 
24.2 ± 10.9 (20) 
24.4 ± 28.6 (20) 
1.6 ± 1.5 (19) 
40.6 ± 5.1 (19) 
31.9 ± 1.6 (18) 
3.1 ± 2.4 (19) 
R
ight Lateral G
astrocnem
ius 
15.1 ± 29 (20) 
60.2 ± 34 (20) 
25.8 ± 10.2 (20) 
15.8 ± 27.3 (20) 
1.3 ± 0.9 (19) 
40.4 ± 4.7 (20) 
32.1 ± 0.9 (17) 
2.5 ± 1.5 (19) 
R
ight M
edial G
astrocnem
ius 
18.2 ± 29.1 (20) 
61.5 ± 30.8 (20) 
25.3 ± 10.2 (19) 
18.6 ± 28.1 (20) 
1.5 ± 0.9 (18) 
40.2 ± 3.5 (20) 
32.7 ± 1.3 (17) 
2.5 ± 1.2 (18) 
R
ight Soleus 
13 ± 25.8 (20) 
56.4 ± 29.6 (20) 
27.6 ± 9.4 (19) 
12.6 ± 23.7 (20) 
2.7 ± 2.9 (19) 
43 ± 6.5 (20) 
32 ± 1.6 (18) 
3 ± 2.7 (19) 
R
ight Tibialis Posterior 
12.4 ± 25.9 (20) 
56.5 ± 34.2 (19) 
27.7 ± 9.5 (20) 
12.4 ± 22.6 (20) 
1 ± 0.9 (19) 
38.9 ± 2.8 (20) 
32.9 ± 1.1 (18) 
1.5 ± 1 (19) 
Left Tibialis A
nterior 
16.8 ± 28.4 (19) 
64.5 ± 35.5 (19) 
25.4 ± 9.4 (20) 
15.7 ± 22.2 (19) 
0.9 ± 0.7 (19) 
40.3 ± 5.9 (20) 
32 ± 1.4 (18) 
2 ± 1 (19) 
Left Peroneus Longus 
18.9 ± 30 (20) 
61.1 ± 32.5 (19) 
25.8 ± 10.4 (20) 
22.4 ± 27.8 (20) 
2 ± 1.6 (19) 
41.1 ± 5.8 (20) 
32 ± 1.8 (19) 
3.7 ± 2.3 (19) 
Left Lateral G
astrocnem
ius 
16.8 ± 29.3 (20) 
60.1 ± 34 (19) 
26 ± 10.6 (20) 
17.8 ± 27.7 (20) 
1.8 ± 1.6 (19) 
39.4 ± 3.9 (20) 
32.1 ± 1.1 (18) 
2.8 ± 1.7 (18) 
Left M
edial G
astrocnem
ius 
20 ± 32.5 (20) 
64 ± 33.8 (19) 
25.8 ± 10.8 (20) 
19.7 ± 29.8 (19) 
1.9 ± 1.3 (19) 
39.7 ± 3.6 (20) 
32.4 ± 1 (18) 
3.9 ± 1.6 (19) 
Left Soleus 
12.3 ± 23.3 (20) 
55.6 ± 27 (19) 
28 ± 8.7 (20) 
13.3 ± 22.9 (19) 
2.4 ± 1.8 (19) 
41.5 ± 4.2 (20) 
32 ± 1.4 (19) 
2.9 ± 2.3 (17) 
Left Tibialis Posterior 
11.5 ± 21.8 (20) 
58.6 ± 30.2 (19) 
27.1 ± 8.5 (20) 
14.1 ± 22 (20) 
1.4 ± 0.8 (19) 
39.5 ± 2.5 (20) 
31.9 ± 1.6 (19) 
2.3 ± 1.3 (19) 
FF: fat fraction; M
TR
: M
agnetisation transfer ratio; FFw
: Fat fraction from
 w
hole m
uscle region of interest. V
alues are m
ean ± standard deviation (num
ber of values). 
T
able e3: B
aseline individual m
uscle values in IB
M
 and m
atched controls 
 M
uscle 
IB
M
 
C
ontrol (IB
M
) 
FF (%
) 
T2 (m
s) 
M
TR
 (p.u.) 
FFw
 (%
) 
FF (%
) 
T2 (m
s) 
M
TR
 (p.u.) 
FFw
 (%
) 
R
ight R
ectus Fem
oris 
19 ± 16.8 (20) 
81.3 ± 29.1 (19) 
20.6 ± 8.2 (9) 
26.8 ± 17.6 (20) 
0.6 ± 0.7 (19) 
41.8 ± 4.5 (16) 
30.7 ± 2.3 (3) 
3.1 ± 1.5 (19) 
R
ight V
astus M
edialis 
31.4 ± 22.7 (20) 
101.2 ± 27.6 (19) 
16.9 ± 6.6 (9) 
37.4 ± 17.5 (20) 
1.4 ± 0.7 (19) 
43.8 ± 4.3 (17) 
31.9 ± 2.4 (5) 
2.7 ± 1 (19) 
R
ight V
astus Interm
edius 
37.6 ± 26.5 (20) 
99.4 ± 30.7 (20) 
15.5 ± 9.1 (15) 
33.9 ± 20.5 (20) 
1.1 ± 0.9 (19) 
39.3 ± 2.4 (18) 
32.8 ± 1.8 (14) 
2.7 ± 1.6 (19) 
R
ight V
astus Lateralis 
49.2 ± 27.8 (20) 
115.9 ± 31.3 (20) 
12.8 ± 8.6 (16) 
44.1 ± 24 (20) 
1.5 ± 0.9 (19) 
42.7 ± 3.7 (17) 
32 ± 1.2 (18) 
3.2 ± 1.1 (19) 
R
ight Sem
im
em
branosus 
19.6 ± 23.8 (20) 
71.2 ± 28.4 (20) 
23.6 ± 8.9 (18) 
23 ± 22.6 (20) 
3.1 ± 2.9 (19) 
47.4 ± 6.6 (18) 
30.8 ± 1.6 (16) 
5.7 ± 2.4 (19) 
R
ight Sem
itendinosus 
19.1 ± 28.3 (20) 
68.6 ± 29.1 (20) 
26.4 ± 7.5 (17) 
23.5 ± 25.8 (20) 
1.1 ± 0.6 (19) 
43.5 ± 3.5 (18) 
32.1 ± 0.8 (17) 
4.4 ± 2.5 (19) 
R
ight B
iceps Fem
oris 
6.6 ± 10.2 (20) 
59.7 ± 17.2 (19) 
28.6 ± 4.3 (18) 
9.5 ± 8.4 (20) 
2.6 ± 1.2 (19) 
48 ± 4 (17) 
30.5 ± 1.1 (17) 
4.1 ± 2.2 (19) 
R
ight A
dductor M
agnus 
34.3 ± 38.5 (20) 
89.1 ± 41 (19) 
22.3 ± 11 (16) 
34.5 ± 32.8 (20) 
2.4 ± 3 (19) 
44.4 ± 5.7 (18) 
31.5 ± 1.7 (17) 
4.6 ± 3.3 (19) 
R
ight Sartorius 
22.4 ± 24.7 (20) 
74.4 ± 24.3 (20) 
24.6 ± 5.5 (11) 
26.7 ± 22.6 (20) 
3.5 ± 3.4 (19) 
44.1 ± 5.8 (16) 
30.8 ± 1.5 (10) 
6.7 ± 2.8 (19) 
R
ight G
racilis 
27.4 ± 31.1 (20) 
71.8 ± 30.1 (20) 
24 ± 8.6 (15) 
29.1 ± 26.4 (20) 
1.6 ± 1.2 (19) 
40.4 ± 3.5 (17) 
32.9 ± 1.6 (17) 
4.5 ± 2 (17) 
Left R
ectus Fem
oris 
29.5 ± 25.5 (20) 
98.3 ± 39.6 (19) 
18.7 ± 7.4 (10) 
33.8 ± 22.9 (20) 
1 ± 0.7 (19) 
39.4 ± 5 (17) 
32.6 ± 1.8 (18) 
3.3 ± 1.8 (19) 
Left V
astus M
edialis 
37.5 ± 25.5 (20) 
114.2 ± 39.1 (19) 
16.4 ± 9.3 (13) 
39.2 ± 20.7 (20) 
1.4 ± 1.1 (19) 
42.3 ± 4.2 (19) 
32.4 ± 1.2 (18) 
3.2 ± 1.2 (19) 
Left V
astus Interm
edius 
38.4 ± 27.5 (20) 
119.4 ± 41.4 (18) 
17.4 ± 8.1 (13) 
38 ± 21.7 (20) 
1.4 ± 1 (19) 
43.4 ± 5 (19) 
31.6 ± 1.7 (18) 
2.4 ± 1.1 (19) 
Left V
astus Lateralis 
46.4 ± 28.5 (20) 
108.4 ± 32.1 (19) 
14.7 ± 9.2 (14) 
44.2 ± 21.1 (20) 
2 ± 1 (19) 
42 ± 2.1 (19) 
31.7 ± 0.9 (18) 
3.9 ± 1.3 (19) 
Left Sem
im
em
branosus 
10.9 ± 15.3 (20) 
55.8 ± 15.9 (20) 
27.6 ± 2.5 (16) 
17.5 ± 14.5 (20) 
2.8 ± 1.7 (18) 
44.5 ± 5.4 (19) 
29.9 ± 1.4 (15) 
5.1 ± 2.5 (18) 
Left Sem
itendinosus 
16.1 ± 26.1 (20) 
60.3 ± 24 (20) 
28.1 ± 4.5 (15) 
21 ± 23.3 (20) 
1.4 ± 0.8 (19) 
42.3 ± 4.6 (19) 
31.4 ± 0.9 (16) 
4.8 ± 2 (18) 
Left B
iceps Fem
oris 
6.1 ± 8.2 (20) 
54.9 ± 14.4 (20) 
29.6 ± 1.7 (16) 
11.4 ± 8.7 (20) 
2.9 ± 2.1 (19) 
44.8 ± 6.1 (19) 
31.4 ± 1.2 (18) 
5.3 ± 2.7 (19) 
Left A
dductor M
agnus 
33.9 ± 36.4 (20) 
87.5 ± 41.5 (19) 
20.3 ± 11.4 (14) 
29 ± 28.5 (20) 
2.5 ± 2.3 (19) 
44 ± 4.9 (19) 
31.1 ± 1.2 (17) 
4.7 ± 3.2 (19) 
Left Sartorius 
25.8 ± 27.4 (20) 
81.5 ± 33.3 (20) 
24.7 ± 7 (13) 
29.9 ± 25.6 (20) 
3.4 ± 3 (19) 
43.7 ± 6.2 (19) 
31.1 ± 1.4 (15) 
7.7 ± 3.3 (19) 
Left G
racilis 
21.2 ± 23.2 (20) 
63.4 ± 22.1 (20) 
26.6 ± 5.8 (12) 
24.5 ± 19.3 (20) 
1.7 ± 1.4 (19) 
39.4 ± 3.8 (19) 
31.9 ± 1.6 (16) 
5 ± 2 (19) 
R
ight Tibialis A
nterior 
7.1 ± 14.6 (17) 
64.2 ± 35 (18) 
25.3 ± 7.1 (13) 
7.4 ± 10.6 (17) 
1 ± 0.5 (18) 
38.5 ± 2.5 (19) 
29.9 ± 1.2 (15) 
1.9 ± 0.9 (17) 
R
ight Peroneus Longus 
9 ± 13.4 (17) 
65.4 ± 32.5 (18) 
26.6 ± 6.6 (18) 
12.4 ± 10.6 (17) 
1.7 ± 1.5 (18) 
41.5 ± 4.8 (18) 
31.4 ± 1.6 (15) 
4 ± 2.5 (17) 
R
ight Lateral G
astrocnem
ius 
20.9 ± 29 (17) 
75.4 ± 37.8 (19) 
23.6 ± 9.9 (18) 
23.3 ± 25.5 (17) 
1.6 ± 1 (18) 
43.2 ± 6.6 (19) 
31.4 ± 1.2 (16) 
3 ± 1.4 (17) 
R
ight M
edial G
astrocnem
ius 
53 ± 32 (17) 
106.4 ± 29.8 (18) 
12.9 ± 9.7 (18) 
50.6 ± 25.7 (17) 
1.6 ± 0.8 (18) 
42.3 ± 4.5 (19) 
32 ± 1.7 (16) 
3.2 ± 1.4 (17) 
R
ight Soleus 
9.2 ± 17.1 (17) 
59.8 ± 26.7 (18) 
27.5 ± 6.7 (16) 
13.1 ± 15.1 (17) 
3.1 ± 2.7 (18) 
43.9 ± 6.2 (19) 
31.5 ± 1.4 (17) 
3.9 ± 2.6 (17) 
R
ight Tibialis Posterior 
3.8 ± 7.2 (17) 
48.6 ± 15.6 (18) 
30.8 ± 3.5 (16) 
5.8 ± 9.2 (17) 
1.3 ± 0.7 (18) 
39.8 ± 2.2 (19) 
32.6 ± 1.1 (17) 
2.1 ± 0.7 (17) 
Left Tibialis A
nterior 
8.9 ± 14.7 (18) 
66.6 ± 33.7 (18) 
26.2 ± 7 (17) 
9.4 ± 11.4 (18) 
1.2 ± 0.7 (18) 
41.9 ± 5.8 (19) 
31.5 ± 1.5 (16) 
2.5 ± 1 (17) 
Left Peroneus Longus 
11 ± 12.3 (18) 
64.7 ± 32.2 (19) 
25.7 ± 7.7 (19) 
15.2 ± 11.4 (18) 
2.4 ± 2.1 (18) 
42.7 ± 6 (19) 
31.2 ± 1.6 (17) 
4.6 ± 2.8 (17) 
Left Lateral G
astrocnem
ius 
18.5 ± 28.3 (18) 
70.7 ± 34.2 (19) 
22.9 ± 10.1 (19) 
23.2 ± 24.5 (18) 
2.1 ± 1.8 (18) 
42.2 ± 5.2 (19) 
31.5 ± 1.1 (16) 
3.5 ± 1.6 (16) 
Left M
edial G
astrocnem
ius 
54.7 ± 29.7 (18) 
111 ± 28.9 (19) 
12.5 ± 8.5 (19) 
52.9 ± 24.5 (18) 
2.9 ± 2.1 (18) 
42.1 ± 6.4 (19) 
32 ± 0.9 (16) 
4.6 ± 1.7 (17) 
Left Soleus 
14.1 ± 20 (18) 
63.6 ± 30.3 (19) 
26.4 ± 8.3 (19) 
17.8 ± 18.8 (18) 
3.2 ± 1.7 (18) 
43.2 ± 4.9 (19) 
31.6 ± 1.4 (17) 
4.1 ± 2.1 (15) 
Left Tibialis Posterior 
6.5 ± 17.5 (18) 
54.3 ± 29.8 (19) 
29.1 ± 6.2 (18) 
9.3 ± 14.7 (18) 
1.6 ± 1 (18) 
40.5 ± 2.3 (19) 
31.5 ± 1.6 (17) 
2.9 ± 1.4 (17) 
FF: fat fraction; M
TR
: M
agnetisation transfer ratio; FFw
: Fat fraction from
 w
hole m
uscle region of interest. V
alues are m
ean ± standard deviation (num
ber of values). 
Table e4: Linear regression of quantitative MRI variables at baseline, at thigh and calf level with all groups combined 
 
Thigh Dependant variable 
FF T2 MTR 
In
de
pe
nd
en
t v
ar
ia
bl
e 
FF 
R   0.92 0.93 
Constant   42.6 31.8 
Slope   1.35 -0.38 
T2 
R 0.92 0 0.95 
Constant -26 0 42.2 
Slope 0.63 0 -0.25 
MTR 
R 0.93 0.95 0 
Constant 73 155 0 
Slope -2.27 -3.55 0 
 
Calf Dependant variable 
FF T2 MTR 
In
de
pe
nd
en
t v
ar
ia
bl
e 
FF 
R   0.93 0.96 
Constant   41.6 31.7 
Slope   1.19 -0.35 
T2 
R 0.93 0 0.97 
Constant -29 0 43.2 
Slope 0.73 0 -0.28 
MTR 
R 0.96 0.97 0 
Constant 84 149 0 
Slope -2.61 -3.38 0 
 
Linear regression of pair-wise comparison of quantitative MRI parameters on an individual muscle basis at thigh and calf level. 
For example at thigh level the equation T2 = 42.6 + 0.92 x fat fraction fits data best, with R = 0.92. All quantitative MRI 
parameters are highly significant (p<0.001for all). Strongest correlation is seen between T2 and MTR at both thigh and calf level. 
Constant and slope are similar at thigh and calf level for equivalent correlations. FF: fat fraction; MTR: magnetisation transfer 
ratio; R: model fit parameter. 
  
Table&e5:&Linear&regression&T2&and&MTR&in&muscles&fat&fraction&in&the&healthy&control&range&(FF&<&4?8%&thigh;&FF&<&4?7%&calf)&in&
IBM&(A)&and&CMT1A&(B)&patients&and&matched&controls&
A" Thigh" Calf"
T2#
R=0?62,&p<0?0001& R=0?52,&p<0?0001&
Co#eff& Std&Error& p& Co#eff& Std&Error& p&
Constant& 38?4& 0?43& <0?0001& 38?0& 0?53& <0.0001&
IBM& 4?0& 0?54& <0?0001& 3?5& 0?57& <0.0001&
FF& 2?52& 0?21& <0?0001& 1?78& 0?25& <0.0001&
MTR#
R=0?61,&p=<0?0001& R=0?39,&p<0?0001&
Co#eff& Std&Error& p& Co#eff& Std&Error& p&
Constant& 32?9& 0?16& <0.0001& 32?3& 0?20& <0?0001&
IBM& R1?5& 0?19& <0.0001& R1?1& 0?21& <0?0001&
FF& R0?74& 0?07& <0.0001& R0?33& 0?09& 0?0007&
&
B" Thigh" Calf"
T2#
R=0?49,&p<0?0001& R=0?59,&p<0?0001&
Co#eff& Std&Error& p& Co#eff& Std&Error& p&
Constant& 38?4& 0?29& <0?0001& 36?6& 0?31& <0?0001&
CMT1A& 1?0& 0?31& 0?0008& 2?0& 0?33& <0?0001&
FF& 2?07& 0?15& <0?0001& 1?87& 0?17& <0?0001&
MTR#
R=0?40,&p<0?0001& R=0?38,&p<0?0001&
Co#eff& Std&Error& p& Co#eff& Std&Error& p&
Constant& 33?0& 0?12& <0?0001& 32?8& 0?14& <0?0001&
CMT1A& R0?3& 0?13& 0?04& R0?7& 0?15& <0?0001&
FF& R0?65& 0?06& <0.0001& R0?40& 0?08& <0?0001&
&
Determinants&of&T2&and&MTR&in&muscles&with&normal&FF.&FF&remains&strongly&correlated&to&both&T2&and&MTR,&however&subject&
group& (patient& =& 1,& control& =0)& also& has& a& significant& effect.& R:& Overall&model& correlation& coefficient;& CMT1A:& CharcotRMarieR
Tooth& disease& type& 1A;& IBM:& inclusion& body& myositis;& FF:& fat& fraction;& MTR:& magnetisation& transfer& ratio;& CoReff:& partial&
regression&coefficient;&p:&significance&level.&
 
T
able e6: C
orrelation of m
uscle strength w
ith M
R
I param
eters in each subject group 
 
 
IB
M
 
C
M
T
 
C
ontrol 
A
rea 
FF 
R
M
A
 
A
rea 
FF 
R
M
A
 
A
rea 
FF 
R
M
A
 
R
ight Q
uadriceps 
IC
C
 
0.665** 
-0.551* 
0.809** 
0.780** 
-0.323 
0.791** 
0.903** 
-0.407* 
0.907** 
p 
0.001 
0.012 
0.000 
0.000 
0.165 
0.000 
0.000 
0.035 
0.000 
L
eft Q
uadriceps 
IC
C
 
0.727** 
-0.778** 
0.917** 
0.848** 
-0.286 
0.860** 
0.900** 
-0.251 
0.905** 
p 
0.000 
0.000 
0.000 
0.000 
0.222 
0.000 
0.000 
0.207 
0.000 
R
ight H
am
strings 
IC
C
 
0.702** 
-0.561* 
0.800** 
0.469* 
-0.252 
0.539* 
0.647** 
-0.264 
0.670** 
p 
0.001 
0.010 
0.000 
0.043 
0.298 
0.017 
0.000 
0.183 
0.000 
L
eft H
am
strings 
IC
C
 
0.706** 
-0.579** 
0.790** 
0.587** 
-0.295 
0.664** 
0.635** 
-0.247 
0.660** 
p 
0.001 
0.007 
0.000 
0.008 
0.220 
0.002 
0.000 
0.215 
0.000 
R
ight A
nterior 
C
om
partm
ent 
IC
C
 
0.780** 
-0.509* 
0.833** 
0.607** 
-0.544* 
0.775** 
0.600** 
-0.195 
0.622** 
p 
0.000 
0.037 
0.000 
0.004 
0.013 
0.000 
0.001 
0.339 
0.001 
L
eft A
nterior 
C
om
partm
ent 
IC
C
 
0.675** 
-0.538* 
0.796** 
0.606** 
-0.634** 
0.759** 
0.672** 
-0.376 
0.677** 
p 
0.002 
0.021 
0.000 
0.005 
0.004 
0.000 
0.000 
0.058 
0.000 
R
ight T
riceps 
Surae 
IC
C
 
0.476* 
-0.626** 
0.769** 
0.531* 
-0.609** 
0.719** 
0.589** 
-0.235 
0.613** 
p 
0.039 
0.007 
0.000 
0.016 
0.004 
0.000 
0.001 
0.248 
0.001 
L
eft T
riceps Surae 
IC
C
 
0.452 
-0.556* 
0.681** 
0.741** 
-0.681** 
0.834** 
0.493** 
-0.010 
0.540** 
p 
0.052 
0.017 
0.002 
0.000 
0.001 
0.000 
0.008 
0.963 
0.004 
 IB
M
: inclusion body m
yositis; T: C
harcot-M
arie-Tooth disease; FF: fat fraction; R
M
A
: rem
aining m
uscle area (see m
ethods for definition); IC
C
: intra-class correlation coefficient; * 
significant correlation p<0.05; ** significant correlation p<0.01. 
 
Table e7:  Comparison*of*outcome*measure*responsiveness*with*previous*studies*in*CMT1A 
Measure' Baseline' Change' p' SRM'
This%study,%1%year%
Mean'calf'fat'fraction'(%)' 1595*±*2490* 1922*±*1947* 09002* 0983*
CMTES'(0<28)' 890*±*591* 093*±*193* ns* 0923*
MRC'lower'limb' 9594*±*1594* B094*±*398* ns* B0911*
SF<36'PF'(0<100%)' 6593*±*2392* B199*±*1499* ns* B0912*
Verhamme4,%5%years,%46%patients%
Adapted'CMTNS^'(0<33)' 1196*±*495* 195*±*390* 09003* 0949*
Nine<hole'peg'test'(s)' 2690*±*1894* 290*±*598* 0902* 0935*
Three<point'grip'(N)' 7*±*32* B693*±*1095* <09001#* B0960*
Ankle'dorsiflexion'(N)' 190*±*74* 091*±*2891* ns* 0900*
Ankle'plantarflexion'(N)' >250+* NA* NA* NA*
Ulnar'CMAP'(mV)' 491*±*195* B094*±*B097* 09001** B0960*
Pareyson6,%2%years,%133%patients%(placebo%arm)%
CMTNS'(0<36)' 1399*±*493* 095*±*297* <0905* 0919*
CMTES'(0<28)' 896*±*396* 095*±*291* <0905* 0923*
CMT'NCS'(0<8)' 592*±*196* B091*±*196* ns* B0906*
Nine<hole'peg'test'(s)' 2394*±*597* 0985*±*297* <0901* 0931*
SF<36'PF'(0<100%)' 6299*±*2597* B191*±*1594* ns* B0907*
Hand'grip'(N)' 8598*±*3898* B699*±*2093* <09001* B0934*
Three'point'pinch'(N)' 6592*±*2994* B396*±*1898* <0905* B0919*
Ankle'dorsiflexion'(N)' 6298*±*4391* B998*±*2397* <09001* B0942*
Ankle'plantarflexion'(N)' 9790*±*5997* B297*±*4797* ns* B0906*
CMAP'sum'(mV)' 791*±*491* 092*±*299* ns* 0908*
*
Values*expressed*mean*±*standard*deviation.*NonBsignificant*(versus*baseline*or*control)*SRM*depicted*in*grey.*#:*
identical* difference* seen* in* controls;* *:* greater* reduction* seen* in* controls* (p=0905);* +:*measurement* limited* to*
250N;* ^:* data* for* this* measurement* collected* retrospectively;* NA:* not* available;* ns:* not* significant;* SRM:*
standardised* response* mean,* calculated* from* published* data* as* mean* change/standard* deviation* change.**
Standard* deviation* in* Pareyson* study* calculated* from* published* 95%* confidence* interval* by* standard* statistical*
formulae:*95%CI*=*mean*B*1.96*s.d.*to*mean*+*1.96*s.d.;*standard*error*mean*=*s.d./√n*
 
  
Figure e1: Correlation of fat fraction with disease duration in IBM and CMT1A patients  
 
* *  
 
Scatter plot of disease duration versus thigh-level (□) and calf-level (x) fat fraction in IBM and CMT1A patients. In 
IBM patients positive correlation between disease duration and mean fat fraction is seen at thigh level 
(rho=0.50,p=0.03) but not calf level (rho=0.27, p=0.28).  In CMT1A patients, strong positive correlations at both 
levels are seen (thigh: rho=0.81,p<0.0001 ; calf: rho=0.89, p<0.0001).  The relationship between disease duration 
and fat fraction appears non-linear in the CMT1A group. 
  
Figure e2:  Correlation of MRI measured remaining muscle area with isometric muscle strength 
 
A B 
* *
*
C D 
 
 
MRI measured RMA of lower limb muscle groups show strong correlation with corresponding strength in IBM (x), 
CMT1A (+) and controls (o). 
A: Right quadriceps. IBM: rho=0.81, p<0.0001; CMT: rho=0.79, p<0.0001; controls: rho=0.91, p<0.0001 
B: Right hamstrings. IBM: rho=0.80, p<0.0001; CMT: rho=0.54, p=0.02; controls: rho=0.67, p<0001 
C: Right anterior compartment. IBM: rho=0.83, p<0.0001; CMT: rho=0.78, p<0.0001; controls: rho=0.62, p=0.0007 
D: Right triceps surae.  IBM: rho=0.77, p<0.0001; CMT: rho=0.72, p<0.0001; controls: rho=0.61, p=0.0009 
  
Figure e3: Correlation of calf fat fraction with severity score (CMTES) in CMT1A patients 
 
 
There is significant correlation between calf muscle fat fraction and CMTES in CMT1A patients (rho=0.63, 
p=0.003).  The relationship appears non-linear. 
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